Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a multicentre study of four European psoriasis cohorts

BACKGROUND: Genetic predictors for treatment response could optimize allocation of biological treatment in patients with psoriasis. There is minimal knowledge about pharmacogenetics of anti‐IL‐17 agents. OBJECTIVES: To assess whether genetic variants in the protein‐coding region or untranslated regi...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vugt, L.J., van den Reek, J.M.P.A., Meulewaeter, E., Hakobjan, M., Heddes, N., Traks, T., Kingo, K., Galluzzo, M., Talamonti, M., Lambert, J., Coenen, M.J.H., de Jong, E.M.G.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004147/
https://www.ncbi.nlm.nih.gov/pubmed/31287604
http://dx.doi.org/10.1111/jdv.15787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004147/
https://www.ncbi.nlm.nih.gov/pubmed/31287604
http://dx.doi.org/10.1111/jdv.15787

Ejemplares similares